Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envofolimab and Lenvatinib with GemCis in Advanced BTC
NCT05410197Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab, lenvatinib in biliary tract cancer (BTC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
envafolimablenvatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05410197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410197.